Author: paroukatos

20 Aug

Posted at 10:16h in Φάρμακα by

A.M. Sharma1, A. Hollander2 and J. Köster3 1University Clinic Benjamin Franklin, Freie Universität, Berlin, 2Bosch Medicentrum, Den Bosch, The Netherlands, and 3Boehringer Ingelheim Pharma KG, Ingelheim, Germany, on behalf of the Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) Study Group Abstract. Aims: This study as sessed the...

20 Aug

Posted at 10:14h in Φάρμακα by

Ronald Clasen, Michael Schupp, Anna Foryst-Ludwig, Christiane Sprang, Markus Clemenz, Maxim Krikov, Christa Tho¨ne-Reineke, Thomas Unger, Ulrich Kintscher Abstract The adipose-specific protein adiponectin has been recently discovered to improve insulin sensitivity. Angiotensin type-1 receptor (AT1R) blockers (ARBs) reduce the incidence of type 2 diabetes mellitus by mostly...

20 Aug

Posted at 10:13h in Φάρμακα by

Stephen C. Benson, Harrihar A. Pershadsingh, Christopher I. Ho, Amar Chittiboyina, Prashant Desai, Michal Pravenec, Nianning Qi, Jiaming Wang, Mitchell A. Avery, Theodore W. Kurtz Abstract The metabolic syndrome is a common precursor of cardiovascular disease and type 2 diabetes that is characterized by the clustering of...

20 Aug

Posted at 10:11h in Μεταβολικό Σύνδρομο by

Jutta M. Nagel1, Anne B. Tietz1, Burkhard Gfke, Klaus G. Parhofer Medizinische Klinik und Poliklinik II, Klinikum Großhadern, Ludwig-Maximilians-Universita¨ t, 81377 Munich, Germany Received 4 January 2006; accepted 3 April 2006 Abstract Intervention studies have shown that angiotensin receptor blocker therapy may reduce the incidence of type 2...

20 Aug

Posted at 10:11h in Μεταβολικό Σύνδρομο by

Giuseppe Mancia, Michele Bombelli, Giovanni Corrao, Rita Facchetti, Fabiana Madotto, Cristina Giannattasio, Fosca Quarti Trevano, Guido Grassi, Alberto Zanchetti, Roberto Sega Abstract-The prevalence of the metabolic syndrome (National Cholesterol Education Program Adult Treatment Panel III criteria) and its relationships with daily life blood pressures, cardiac damage,...

20 Aug

Posted at 10:09h in Μεταβολικό Σύνδρομο by

Implications for treating insulinresistant hypertension and cardiovascular disease The angiotensin II type 1 receptor blocker (ARB) telmisartan was reported to activate the peroxisome proliferator-activated receptor-_ (PPAR_) in transactivation assays, whereas other ARBs, with the possible exception of irbesartan, did not (1). Telmisartan also induced adipogenesis and...

20 Aug

Posted at 10:09h in Μεταβολικό Σύνδρομο by

Theodore W. Kurtz, MD epartment of Laboratory Medicine, University of California, San Francisco, California, USA ABSTRACT The metabolic syndrome is characterized by the clustering of insulin resistance, dyslipidemia, and hypertension and is associated with increased risk of cardiovascular disease and type 2 diabetes mellitus. However, older antihypertensive agents...

20 Aug

Posted at 10:08h in Μεταβολικό Σύνδρομο by

T.W. Kurtz Abstract Hypertension commonly occurs as part of a genetically complex disorder of carbohydrate and lipid metabolism known as the metabolic syndrome. Most current antihypertensive drugs appear ineffective against the metabolic syndrome, which is a strong predictor of cardiovascular disease and death in affected patients. Angiotensin...

20 Aug

Posted at 10:07h in Μεταβολικό Σύνδρομο by

TheodoreW. Kurtza and Michal Pravenecb Several lines of evidence suggest that angiotensinconverting enzyme (ACE) inhibitors and some angiotensin II receptor blockers (ARBs) may improve insulin sensitivity and decrease the risk for type 2 diabetes. It is widely assumed that the potential antidiabetic properties of these agents...